AR116605A1 - Compuestos bifuncionales que comprenden péptidos de insulina y péptidos de egf(a) - Google Patents
Compuestos bifuncionales que comprenden péptidos de insulina y péptidos de egf(a)Info
- Publication number
- AR116605A1 AR116605A1 ARP190102838A ARP190102838A AR116605A1 AR 116605 A1 AR116605 A1 AR 116605A1 AR P190102838 A ARP190102838 A AR P190102838A AR P190102838 A ARP190102838 A AR P190102838A AR 116605 A1 AR116605 A1 AR 116605A1
- Authority
- AR
- Argentina
- Prior art keywords
- peptides
- egf
- compounds including
- bifunctional compounds
- including insulin
- Prior art date
Links
- 230000001588 bifunctional effect Effects 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 102000004877 Insulin Human genes 0.000 title 1
- 108090001061 Insulin Proteins 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 2
- 208000032928 Dyslipidaemia Diseases 0.000 abstract 1
- 208000017170 Lipid metabolism disease Diseases 0.000 abstract 1
- 102000037865 fusion proteins Human genes 0.000 abstract 1
- 108020001507 fusion proteins Proteins 0.000 abstract 1
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical class N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6454—Dibasic site splicing serine proteases, e.g. kexin (3.4.21.61); furin (3.4.21.75) and other proprotein convertases
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente se refiere a proteínas de fusión bifuncionales unidas covalentemente que comprenden análogos de insulina y EGF(A) o sus derivados y análogos de EGF(A), y su uso farmacéutico. Además, la presente se refiere a composiciones farmacéuticas que comprenden tales compuestos bifuncionales, y al uso de tales compuestos para el tratamiento o prevención de afecciones médicas relacionadas con la diabetes y la dislipidemia asociada con diabetes.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18198892 | 2018-10-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR116605A1 true AR116605A1 (es) | 2021-05-26 |
Family
ID=64017248
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP190102838A AR116605A1 (es) | 2018-10-05 | 2019-10-04 | Compuestos bifuncionales que comprenden péptidos de insulina y péptidos de egf(a) |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US11649269B2 (es) |
| EP (1) | EP3861017A1 (es) |
| JP (1) | JP7434299B2 (es) |
| CN (1) | CN112789289A (es) |
| AR (1) | AR116605A1 (es) |
| MA (1) | MA53809A (es) |
| TW (1) | TW202028229A (es) |
| WO (1) | WO2020070276A1 (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE055417T2 (hu) | 2016-12-09 | 2021-11-29 | Akston Biosciences Corp | Inzulin-Fc fúziók és alkalmazási eljárások |
| LT3892628T (lt) | 2018-06-29 | 2022-12-12 | Akston Biosciences Corporation | Itin ilgai veikiantys insulino-fc sulieti baltymai ir naudojimo būdai |
| US11267862B2 (en) | 2018-06-29 | 2022-03-08 | Akston Biosciences Corporation | Ultra-long acting insulin-Fc fusion proteins and methods of use |
| CA3159486A1 (en) | 2019-12-19 | 2021-06-24 | Thomas M. Lancaster | Ultra-long acting insulin-fc fusion proteins and methods of use |
| US11186623B2 (en) | 2019-12-24 | 2021-11-30 | Akston Bioscience Corporation | Ultra-long acting insulin-Fc fusion proteins and methods of use |
| US11192930B2 (en) | 2020-04-10 | 2021-12-07 | Askton Bioscences Corporation | Ultra-long acting insulin-Fc fusion protein and methods of use |
| BR112022020486A2 (pt) | 2020-04-10 | 2023-01-17 | Akston Biosciences Corp | Imunoterapia específica de antígeno para proteínas de fusão de covid-19 e métodos de uso |
| US11198719B2 (en) | 2020-04-29 | 2021-12-14 | Akston Biosciences Corporation | Ultra-long acting insulin-Fc fusion protein and methods of use |
| CA3193453A1 (en) | 2020-09-30 | 2022-04-07 | Beijing Ql Biopharmaceutical Co., Ltd. | Polypeptide conjugates and methods of uses |
| US11667689B2 (en) | 2021-07-23 | 2023-06-06 | Akston Biosciences Corporation | Insulin-Fc fusion proteins and methods of use to treat cancer |
| CN115850385B (zh) * | 2022-07-04 | 2023-08-11 | 北京惠之衡生物科技有限公司 | 一种促表达肽及其应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8962794B2 (en) | 2007-08-15 | 2015-02-24 | Novo Nordisk A/S | Insulins with an acyl moiety comprising repeating units of alkylene glycol containing amino acids |
| MX2010009850A (es) | 2008-03-18 | 2010-09-30 | Novo Nordisk As | Analogos de insulina acilados y etabilizados contra proteasas. |
| EP2296694B1 (en) | 2008-04-23 | 2015-08-05 | Amgen Inc. | Neutralizing proprotein convertase subtilisin kexin type 9 (pcsk9) variants and uses thereof |
| GB201005005D0 (en) * | 2010-03-25 | 2010-05-12 | Angeletti P Ist Richerche Bio | New vaccine |
| EP2721063A4 (en) | 2011-06-20 | 2015-01-14 | Hoffmann La Roche | PCSK9 BINDING POLYPEPTIDES AND METHOD OF USE THEREOF |
| RU2016137264A (ru) | 2014-02-21 | 2018-03-26 | МЕДИММЬЮН, ЭлЭлСи | Слияния антитела к pcsk9~glp-1 и способы применения |
| CN104558199B (zh) | 2014-09-05 | 2018-07-06 | 成都康弘生物科技有限公司 | 一种治疗高胆固醇血症的融合蛋白制备及其用途 |
| WO2016164762A1 (en) | 2015-04-08 | 2016-10-13 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor egf-a and intracellular domain mutants and methods of using the same |
| AU2016311283B2 (en) | 2015-08-25 | 2020-10-08 | Novo Nordisk A/S | Novel insulin derivatives and the medical uses hereof |
| CA3010756A1 (en) | 2016-01-13 | 2017-07-20 | Novo Nordisk A/S | Egf(a) analogues with fatty acid substituents |
-
2019
- 2019-10-04 MA MA053809A patent/MA53809A/fr unknown
- 2019-10-04 EP EP19783295.9A patent/EP3861017A1/en active Pending
- 2019-10-04 TW TW108135986A patent/TW202028229A/zh unknown
- 2019-10-04 CN CN201980064514.4A patent/CN112789289A/zh active Pending
- 2019-10-04 WO PCT/EP2019/076889 patent/WO2020070276A1/en active Application Filing
- 2019-10-04 US US17/281,813 patent/US11649269B2/en active Active
- 2019-10-04 JP JP2021518432A patent/JP7434299B2/ja active Active
- 2019-10-04 AR ARP190102838A patent/AR116605A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022504153A (ja) | 2022-01-13 |
| WO2020070276A1 (en) | 2020-04-09 |
| CN112789289A (zh) | 2021-05-11 |
| US20220009989A1 (en) | 2022-01-13 |
| JP7434299B2 (ja) | 2024-02-20 |
| US11649269B2 (en) | 2023-05-16 |
| TW202028229A (zh) | 2020-08-01 |
| MA53809A (fr) | 2022-01-12 |
| EP3861017A1 (en) | 2021-08-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR116605A1 (es) | Compuestos bifuncionales que comprenden péptidos de insulina y péptidos de egf(a) | |
| BR112017001940A2 (pt) | proteínas de fusão de interleucina-2/receptor alfa de interleucina-2 e processos de uso | |
| CO2017012995A2 (es) | Derivados análogos de heteroarilos/arilo actvos como reguladores nrf2 y composiciones farmacéuticas de los mismos | |
| CY1123307T1 (el) | Πρωτεϊνες συγχωνευσης fgf21 μακρας δρασης και φαρμακευτικες συνθεσεις που τις περιλαμβανουν | |
| UY37048A (es) | Nuevos indazoles sustituidos, procedimientos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos | |
| BR112017006178A2 (pt) | região fc, anticorpos, formulação farmacêutica e usos dos anticorpos | |
| CL2020000422A1 (es) | Composiciones de glp-1 y sus usos. | |
| CL2012000092A1 (es) | Compuestos derivados de piridina y pirazina o una sal de los mismos, moduladores de proteina quinasa cdk9; composicion farmaceutica que los comprende, util para el tratamiento del cancer, hipotrofia cardiaca, vih y enfermedades inflamatorias. | |
| BR112016029848A2 (pt) | proteínas de fusão mic-1 e utilizações das mesmas | |
| BR112015032875A2 (pt) | derivados de peptídeos do tipo glp-1, e usos dos mesmos | |
| BR112018013820A2 (pt) | análogos de egf(a) com substituintes de ácido graxo | |
| CL2012001722A1 (es) | Compuestos derivados de 3-hidroxi-5-arilisotiazol, agonistas del receptor 40 acoplado a la proteina g (gpr40); composición farmacéutica que los comprende; y método para el tratamiento o la prevención de la diabetes. | |
| CL2015002608A1 (es) | Compuesto de amino-pirazol y usos medicinales relacionados. | |
| BR112016000565A2 (pt) | polipeptídeo cíclico, derivado ou análogo do mesmo e seu uso modulador alostérico, composição farmacêutica, processo para produzir a mesma | |
| AR099569A1 (es) | Derivados de insulina y los usos médicos de estos | |
| UY37646A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| AR106364A1 (es) | Derivados de insulina y sus usos médicos | |
| ECSP20062930A (es) | Compuestos agonistas del factor de diferenciación del crecimiento 15 y sus métodos de uso | |
| CL2019001586A1 (es) | Insulina que contiene composiciones farmacéuticas. | |
| ECSP19083930A (es) | Compuesto de insulina acilada | |
| MX2021004331A (es) | Composiciones estables de semaglutida y usos de las mismas. | |
| UY38069A (es) | Péptidos de la cadena b de la relaxina lipidados modificados y su uso terapéutico | |
| AR114324A1 (es) | Péptidos de la cadena b de la relaxina lipidados modificados y su uso terapéutico | |
| BR112019023260A2 (pt) | Fatores de crescimento de fibroblastos recombinantes modificados e seus usos terapêuticos | |
| EA202191478A1 (ru) | Гетероароматические соединения в качестве ингибиторов ванина |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |